4.5 Article

Malignancies Diagnosed During Pregnancy and Treated With Chemotherapy or Other Modalities (Review of 27 Cases) Multicenter Experiences

Journal

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Volume 20, Issue 5, Pages 698-703

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1111/IGC.0b013e3181daaf3e

Keywords

Pregnancy; Cancer; Chemotherapy; Outcome; Fetus

Ask authors/readers for more resources

Background: Cancer is the second leading cause of death in women of reproductive age. The most common tumors diagnosed during pregnancy are breast and cervix cancer, Hodgkin lymphoma and non-Hodgkin lymphoma, leukemias, and malignant melanoma. The aim of therapy in pregnancy is to give optimal treatment to the mother without harm to the fetus. In the first trimester, organogenesis continues, so chemotherapy should not be given because of increasing risk of spontaneous abortion, fetal malformation, and mortality. We evaluated mostly seen tumors during pregnancy and assessed treatment type and outcome of pregnancy after chemotherapy in our population. Methods: We retrospectively analyzed 27 patients who have been treated during pregnancy or after the delivery because of several malignancies. Results: The tumors associated with pregnancy were breast cancer, hematologic malignancies, gynecologic malignancies, sarcomas, and others. The chemotherapy regimens were given in 17 of 27 patients in the second or third trimester of pregnancy. Four of the patients were diagnosed with cervical cancer, hemangiopericytoma, chronic myeloid leukemia, and breast cancer during the first trimester, so their pregnancies were ended by therapeutic abortion. Although 1 of the 3 fetuses who were exposed to chemotherapy in utero at the second or third trimester was born prematurely and low birth weight was diagnosed in the other 2 fetuses, fetal malformation was not seen in any of them. There were 7 normal and 9 cesarean deliveries. Twenty-three healthy babies survived from 27 pregnancies, of whom 17 babies were exposed to chemotherapeutic agents. Conclusions: We reported herein 27 patients with malignancies diagnosed during pregnancy; 17 patients received chemotherapy during the gestational period without any fetal or maternal abnormalities. Because of the low incidence of malignancy during pregnancy, our report is noteworthy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Pinar Gursoy, Ali Murat Tatli, Dilek Erdem, Erdem Goker, Emir Celik, Nebi Serkan Demirci, Abdullah Sakin, Muhammed Mustafa Atci, Ertugrul Bayram, Tugba Akin Telli, Burak Bilgin, Ahmet Bilici, Baran Akangunduz, Sevinc Balli, Ahmet Demirkazik, Fatih Selcukbiricik, Serkan Menekse, Eyyup Cavdar, Akin Ozturk, Esma Turkmen Bekmez, Serdal Turhal, Sadettin Kilickap, Hasan Cagri Yildirim, Basak Oyan, Asude Aksoy, Fatma Paksoy Turkoz, Engin Kut, Nuran Katgi, Teoman Sakalar, Murat Akyol, Halil Ibrahim Ellez, Atakan Topcu, Atike Pinar Erdogan, Kezban Nur Pilanci, Engin Hedem, Haci Arak, Nadiye Akdeniz, Ozkan Alan, Burcu Yapar, Deniz Nart, Perran Fulden Yumuk

Summary: This study compares the survival of NSCLC patients with rare EGFR exon 18 and exon 20 mutations who received first- and second-generation TKIs. The results show that patients with complex mutations exhibit similar sensitivity to TKI treatment as those with classical mutations, suggesting that both first- and second-generation EGFR-TKIs should be considered for patients with rare exon 18 and exon 20 EGFR mutations.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Oncology

The Predictive Importance of Body-Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer

Levent Emirzeoglu, Serdar Arici, Ahmet Bilgehan Sahin, Birol Ocak, Naziye Ak, Seval Ay, Elkhan Mammadov, Hande Turna, Ahmet Bilici

Summary: This study investigated the effects of BMI on the response to neoadjuvant chemotherapy in Turkish patients with breast cancer. The results showed that a high BMI and HR positivity were associated with a poor response to treatment.

BREAST CARE (2023)

Article Oncology

Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

Ahmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, Berna Oksuzoglu, Ahmet Sezer, Nuri Karadurmus, Erdem Cubukcu, Mehmet Ali Nahit Sendur, Sercan Aksoy, Dilek Erdem, Gul Basaran, Burcu Cakar, Abdallah T. M. Shbair, Cagatay Arslan, Ahmet Taner Sumbul, Sema Sezgin Goksu, Ibrahim Karadag, Irfan Cicin, Mahmut Gumus, Fatih Selcukbiricik, Hakan Harputluoglu, Umut Demirci

Summary: This real-life study suggests that adding pertuzumab to neoadjuvant chemotherapy with trastuzumab enables a higher pathological complete response rate in HER2+ breast cancer patients. Additionally, pathological complete response is associated with lower relapse rates and better event-free survival time.

ACTA ONCOLOGICA (2023)

Article Environmental Sciences

Determination of Radionuclides Concentrations in Surface Soil Samples in the District of Bandirma, Balikesir

Ahmet Bilici, Ismail Kocak, Sevim Bilici, Mirac Kamislioglu, Serpil Akozcan, Bulent Buyuk, S. Selin

Summary: The concentrations of natural and artificial radionuclides were measured in soil samples, and radiological hazard indices were calculated. The results showed that the measured radioactivity concentrations were below the world average.

ENVIRONMENTAL FORENSICS (2023)

Article Geochemistry & Geophysics

Markov Chain transition probability modeling of radon gas records and future projection possibility determination

Ahmet Bilici, Fatih Kulahci, Sevim Bilici, Zekai Sen

Summary: Markov Chain models are used to subdivide data based on mean value and standard deviations. The transition probabilities between these categories are calculated, and the procedure is repeated until steady-state transition probability values are obtained. This modeling approach is convenient for radon gas transient measurement records.

JOURNAL OF ATMOSPHERIC AND SOLAR-TERRESTRIAL PHYSICS (2023)

Article Oncology

Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study

Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Sabin Goktas Aydin, Emrah Eraslan, Muhammed Ali Kaplan, Birol Ocak, Sema Sezgin Goksu, Semra Paydas, Fahri Akgul, Sumeyye Derin, Yakup Ergun, Emre Yekeduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin, Ozlem Ozkul, Hacer Demir, Dilek Erdem, Mehmet Besiroglu, Olcun Umit Unal, Ramazan Acar, Lokman Koral, Suleyman Sahin, Teoman Sakalar, Aykut Bahceci, Ahmet Ozveren, Ulug Mutlu Gunaydin, Mehmet Metin Seker, Veli Sunar, Pinar Dal, Mehmet Artac, Serdar Turhal

Summary: This study retrospectively analyzed the medical records of patients with non-adipocytic metastatic soft tissue sarcoma treated with pazopanib in 37 oncology clinics in Turkey. The results showed that pazopanib is effective and well-tolerated in the treatment of this disease, with better outcomes observed when used earlier and in patients with good performance status.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Medicine, General & Internal

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

Yasin Kutlu, Sabin Goktas Aydin, Ahmet Bilici, Bala Basak Oven, Omer Fatih Olmez, Ozgur Acikgoz, Jamshid Hamdard

Summary: This study investigated the prognostic role of inflammatory markers in ES-SCLC patients treated with atezolizumab plus chemotherapy and evaluated the efficacy and safety of this treatment. The results showed that the addition of atezolizumab to chemotherapy had a high objective response rate and improved overall survival. Prognostic factors such as limited-stage disease, the presence of prophylactic cranial irradiation, liver metastasis, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) were identified.

MEDICINE (2023)

Article Oncology

The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data

Sabin Goktas Aydin, Omer Fatih Olmez, Oguzhan Selvi, Caglayan Geredeli, Ferhat Ozden, Ahmet Bilici, Ozgur Acikgoz, Ebru Karci, Yasin Kutlu, Jamshid Hamdard, Ahmet Aydin

Summary: This study investigated the role of MSI and CDX-2 status determined by immunohistochemistry, along with inflammatory markers and pathological parameters, in predicting disease recurrence in stage II and III colon cancer. The loss of CDX-2 was found to be an independent prognostic factor for DFS and disease recurrence in early-stage colon cancer.

JOURNAL OF GASTROINTESTINAL CANCER (2023)

Article Medicine, General & Internal

SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

Sabin Goktas Aydin, Yasin Kutlu, Harun Muglu, Ozgur Acikgoz, Ahmet Aydin, Ahmet Bilici, Omer Fatih Olmez, Dilek Unal, Ebru Karci, Ozcan Yildiz

Summary: This study investigated the effects of metastasis-directed stereotactic body radiotherapy (SBRT) on survival in patients with metastatic castration-resistant prostate cancer who developed oligo-progression under anti-androgen therapy. The results showed that patients who received SBRT while continuing the same antiandrogen therapy had a higher 12-month progression-free survival rate. Therefore, metastasis-directed SBRT with continuation of the same antiandrogen therapy should be prioritized only in selected cases.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI (2023)

Meeting Abstract Oncology

Locoregional Treatment Improves Survival in De Novo Bone-only Metastatic Breast Cancer: Long-term Results of the Prospective, Multi-institutional Study - Protocol BOMET MF14-01

Atilla Soran, Lutfi Dogan, Arda Isik, Serdar Ozbas, Didem Can-Trabulus, Umut Demirci, Hasan Karanlik, Aykut Soyder, Ahmet Dag, Ahmet Bilici, Mutlu Dogan, Mehmet Ali Nahit Sendur, Hande Koksal, Mehmet Ali Gulcelik, Neslihan Cabioglu, Levent Yeniay, Zafer Utkan, Nuri Karadurmus, Gul Daglar, Turgay Simsek, Birol Yildiz, Cihan Uras, Mustafa Tukenmez, Cihangir Ozaslan, Gokturk Maralcan, Suat Kutun, Niyazi Karaman, Osman Toktas, Ahmet Ozgen Yildirim, Mufide Nuran Akcay, Vahit Ozmen, Efe Sezgin

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Medicine, General & Internal

Clinicopathological and Survival Characteristics of Mismatch Repair Status and PD-1 Expression in Serous Ovarian Cancer

Fatma Olmez, Suleyman Cemil Oglak, Sedat Akgol, Omer Fatih Olmez, Ahmet Bilici, Ozgur Akbayr, Zeynep Gedik Ozkose, Esra Can, Omer Unal, Hicran Acar Sirinoglu

Summary: This study aimed to evaluate the clinicopathological characteristics and clinical outcomes of mismatch repair (MMR) deficiency in serous ovarian cancer (SOC) through immunohistochemistry (IHC) for MMR genes. The results showed that MMR-deficient SOC were diagnosed at earlier stages compared to MMR proficient cases. PD-1 expression was significantly higher in MMR-deficient cases, and MMR status was significantly associated with disease-free survival (DFS) and overall survival (OS).

JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN (2023)

Meeting Abstract Oncology

The modified glasgow prognostic score (MGPS) and the mortality prediction MODEL II (MPM II) CAN predict mortality in patients with breast cancer admitted to intensive care: A retrospective cohort study.

Omer Fatih Olmez, Burcu Tunay, Ahmet Bilici, Ayberk Bayramgil, Gunes Dorukhan Cavusoglu, Huseyin Oz

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Pazopanib in metastatic soft tissue sarcoma (STS): Results of a multi-institutional observational study.

Ahmet Bilici, Sinan Koca, Mustafa Karaagac, Emrah Eraslan, Birol Ocak, Sabin Goktas Aydin, Sema Sezgin Goksu, Semra Paydas, Sumeyye Derin, Yakup Ergun, Emre Yekegunduz, Cihan Erol, Deniz Tataroglu Ozyukseler, Atike Gokcen Demiray, Mustafa Karaca, Zeynep Gulsum Guc, Serkan Menekse, Havva Yesil Cinkir, Ozge Gumusay, Abdullah Sakin

JOURNAL OF CLINICAL ONCOLOGY (2022)

Meeting Abstract Oncology

Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Ahmet Bilici, Omer Fatih Olmez, Ahmet Sezer, Berna Oksuzoglu, Muhammet Ali Kaplan, Nuri Karadurmus, Erdem Cubukcu, Mehmet A. N. Sendur, Sercan Aksoy, Dilek Erdem, Gul Basaran, Burcu Cakar, Mesut Seker, Cagatay Arslan, Sema Sezgin Goksu, Irfan Cicin, Mahmut Gumus, Fatih Selcukbiricik, Hakan Harputluoglu, Kaan Helvaci

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Medicine, General & Internal

FACTORS PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER

Emine Yildirim, Sibel Bektas, Sabin Goktas Aydin, Ahmet E. R. Muzaffer, Irem Yanik, Perihan Ozkan Gumuskaya, Barbaros Utku Yilmaz, Ahmet Bilici, Mustafa Oncel

Summary: This study investigated the effect of hematological and histopathological parameters on the response to chemotherapy in patients with gastric cancer. The results showed that patients without perineural invasion had a better pathological complete response to chemotherapy.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI (2022)

No Data Available